AstraZeneca Pharma India has been the best-performing multinational (MNC) pharma stock with gains of 130 per cent over the last one year. The growth trigger for the company is its presence in therapeutic categories such diabetes, respiratory, cardiovascular and oncology segments.
The segments are not only large in revenue terms, but also growing at a faster rate than the overall pharma market. For example, diabetes medications which account for 38 per cent of the company’s revenues, is the second largest category in the Indian pharma market with sales of over Rs 14,400 ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Copyrights © 2020 Business Standard Private Ltd. All rights reserved.
